Table 1 |
||||||
|
Tumor and serum vascular endothelial growth factor (VEGF) in relation to clinical, pathological and biological characteristics in breast cancer patients |
||||||
| Tumor VEGF |
Serum VEGF |
|||||
|
|
||||||
| Number of cases |
% positive cells [median (range)] |
P |
Number of cases |
Serum level (pg/ml) [median (range)] |
P |
|
|
|
||||||
| Age |
||||||
| 51–70 years |
40 |
65 (10–100) |
0.91 |
43 |
180.5 (30.8–768.4) |
0.11 |
| > 70 years |
22 |
65 (5–100) |
26 |
241.5 (22.7–953.5) |
||
| Histotype |
||||||
| Ductal |
53 |
70 (5–100) |
56 |
189.9 (30.8–953.5) |
0.71 |
|
| Others |
9 |
50 (10–75) |
13 |
238.4 (22.7–456.8) |
||
| Tumor size |
||||||
| ≤ 2 cm |
42 |
70 (10–100) |
0.09 |
49 |
193.6 (30.8–953.5) |
0.42 |
| > 2 cm |
20 |
47.5 (5–90) |
19 |
144.5 (22.7–561.0) |
||
| Node status |
||||||
| Node-negative |
30 |
70 (15–95) |
0.22 |
34 |
204.4 (36.6–768.4) |
0.50 |
| Node-positive |
27 |
60 (5–100) |
25 |
144.5 (22.7–953.5) |
||
| Grade |
||||||
| 1–2 |
38 |
75 (10–100) |
0.05 |
40 |
183.7 (30.8–768.4) |
0.348 |
| 3 |
11 |
35 (5–90) |
11 |
144.5 (36.3–953.5) |
||
| Steroid status |
||||||
| ER-positive |
43 |
70 (10–95) |
0.05 |
47 |
187.0 (30.8–953.5) |
0.45 |
| ER-negative |
10 |
30 (5–90) |
10 |
270.8 (48.3–768.4) |
||
| PgR-positive |
31 |
65 (10–95) |
0.72 |
34 |
187.1 (30.8–953.5) |
0.70 |
| PgR-negative |
22 |
67.5 (5–95) |
23 |
193.6 (48.3–674.1) |
||
|
|
||||||
|
ER, estrogen receptor; PgR, progesterone receptor. |
||||||
|
Granato et al. Breast Cancer Res 2004 6:R38 doi:10.1186/bcr745 |
||||||
